Northwell Health and Northwell’s Feinstein Institutes for Medical Research have entered into a clinical trial agreement to participate in BioRestorative Therapies’ Phase II clinical trial of BRTX-100 for the treatment of chronic lumber disc disease (cLDD).

A new cell-based therapeutic, BRTX-100 is designed to target areas of the body having little blood flow.

An office-based injection procedural approach of BRTX-100 introduces patient’s own cultured mesenchymal stem cells to target the harsh environment of the intervertebral disc.

Designed to assess the preliminary efficacy and safety of a single dose of BRTX-100, the double-blinded, randomised, controlled, and prospective study will enrol a total of around 99 patients.

Subjects selected at up to 15 US clinical sites will be randomised into 2:1 ratio to receive either BRTX-100 or control.

BioRestorative CEO Lance Alstodt said: “We are delighted to enter into such an agreement with Northwell and their world class team of non-surgical and surgical spine clinicians and researchers across the disciplines.

“We hope to identify other areas where our two organisations can work closely with one another. Research is a very obvious area of focus for both of us and we look forward to exploring strategic possibilities to enhance and strengthen our relationship with Northwell.”

BioRestorative’s cell-based therapy candidate ThermoStem uses brown adipose derived stem cells to target obesity and metabolic disorders.

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.